Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 28, 2023
Daily News
February 28, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
- Japan Panel Backs Approval of 1st Nasal Flu Vaccine
February 28, 2023
- Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- Enhertu Approved in China for HER2 Positive Breast Cancer
February 28, 2023
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…